Soluble Coxsackievirus B3 3C Protease Inhibitor Prevents Cardiomyopathy in an Experimental Chronic Myocarditis Murine Model

Virus Research

Volumn 199, Issue , 2015, Pages 1-8

  Lim, Byung Kwan ^b   Yun, Soo Hyeon ^a   Ju, Eun Seon ^a   Kim, Bo Kyoung ^c   Lee, You Jung ^a   Yoo, Dong Kyeom ^d   Kim, Young Chul ^c   Jeon, Eun Seok ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Jungwon University   (South Korea)

^c Gwangju Institute of Science and Technology (GIST)   (South Korea)

^d Samsung Medical Center   (South Korea)

Author keywords

Antiviral agent; Chronic; Coxsackievirus; Inhibitors; Myocarditis

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; TROPONIN I; UNCLASSIFIED DRUG; WATER SOLUBLE 3CP INHIBITOR; 3C PROTEASES; CYSTEINE PROTEINASE; PROTEINASE INHIBITOR; VIRUS PROTEIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; COXSACKIE VIRUS B3; ECHOCARDIOGRAPHY; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE INJURY; HUMAN; HUMAN CELL; MICROBIOLOGICAL PARAMETERS; MOUSE; MURINE MODEL; NONHUMAN; PHENOTYPE; PLAQUE FORMING CELL ASSAY; PRIORITY JOURNAL; SURVIVAL RATE; VALVULAR HEART DISEASE; VIRUS MYOCARDITIS; VIRUS TITER; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIOMYOPATHIES; COXSACKIEVIRUS INFECTIONS; DBA MOUSE; DISEASE MODEL; DRUG EFFECTS; ENTEROVIRUS B; ENZYMOLOGY; HEART; HEART FUNCTION TEST; MALE; SURVIVAL; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

COXSACKIEVIRUS; ENTEROVIRUS; MURINAE; MUS;

ANIMALS; ANTIVIRAL AGENTS; CARDIOMYOPATHIES; COXSACKIEVIRUS INFECTIONS; CYSTEINE ENDOPEPTIDASES; DISEASE MODELS, ANIMAL; ENTEROVIRUS B, HUMAN; HEART; HEART FUNCTION TESTS; MALE; MICE, INBRED DBA; PROTEASE INHIBITORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD; VIRAL PROTEINS;

EID: 84923571420     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2014.11.030     Document Type: Article

References (21)

1. Cooper L.T. Myocarditis: From Bench to Bedside 2002, Humana Press.
2. Herskowitz A., Beisel K.W., Wolfgram L.J., Rose N.R. Coxsackievirus B3 murine myocarditis: wide pathologic spectrum in genetically defined inbred strains. Hum. Pathol. 1985, 16(7):671-673.
3. Huber S.A., Lodge P.A. Coxsackievirus B-3 myocarditis. Identification of different pathogenic mechanisms in DBA/2 and Balb/c mice. Am. J. Pathol. 1986, 122(2):284-291.
4. Kandolf R., Klingel K., Zell R., Selinka H.C., Raab U., Schneider-Brachert W., Bultmann B. Molecular pathogenesis of enterovirus-induced myocarditis: virus persistence and chronic inflammation. Intervirology 1993, 35(1-4):140-151.
5. Khatib R., Probert A., Reyes M.P., Khatib G., Chason J.L. Mouse strain-related variation as a factor in the pathogenesis of coxsackievirus B3 murine myocarditis. J. Gen. Virol. 1987, 68(Pt 12):2981-2988.
6. Kim J.M., Lim B.K., Ho S.H., Yun S.H., Shin J.O., Park E.M., Kim D.K., Kim S., Jeon E.S. TNFR-Fc fusion protein expressed by in vivo electroporation improves survival rates and myocardial injury in coxsackievirus induced murine myocarditis. Biochem. Biophys. Res. Commun. 2006, 344(3):765-771.
7. Kim B.K., Kim J.H., Kim N.R., Lee W.G., Lee S.D., Yun S.H., Jeon E.S., Kim Y.C. Development of anti-coxsackievirus agents targeting 3C protease. Bioorg. Med. Chem. Lett. 2012, 22(22):6952-6956.
8. Klingel K., Kandolf R. The role of enterovirus replication in the development of acute and chronic heart muscle disease in different immunocompetent mouse strains. Scand. J. Infect. Dis. Suppl. 1993, 88:79-85.
9. Klingel K., Hohenadl C., Canu A., Albrecht M., Seemann M., Mall G., Kandolf R. Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replication, tissue damage, and inflammation. Proc. Natl. Acad. Sci. U. S. A. 1992, 89(1):314-318.
10. Knowlton K.U., Jeon E.S., Berkley N., Wessely R., Huber S. A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3. J. Virol. 1996, 70(11):7811-7818.
11. Koide H., Kitaura Y., Deguchi H., Ukimura A., Kawamura K., Hirai K. Genomic detection of enteroviruses in the myocardium-studies on animal hearts with coxsackievirus B3 myocarditis and endomyocardial biopsies from patients with myocarditis and dilated cardiomyopathy. Jpn. Circ. J. 1992, 56(10):1081-1093.
12. Lim B.K., Choe S.C., Shin J.O., Ho S.H., Kim J.M., Yu S.S., Kim S., Jeon E.S. Local expression of interleukin-1 receptor antagonist by plasmid DNA improves mortality and decreases myocardial inflammation in experimental coxsackieviral myocarditis. Circulation 2002, 105(11):1278-1281.
13. Lim B.K., Choi J.H., Nam J.H., Gil C.O., Shin J.O., Yun S.H., Kim D.K., Jeon E.S. Virus receptor trap neutralizes coxsackievirus in experimental murine viral myocarditis. Cardiovasc. Res. 2006, 71(3):517-526.
14. Lim B.K., Xiong D., Dorner A., Youn T.J., Yung A., Liu T.I., Gu Y., Dalton N.D., Wright A.T., Evans S.M., Chen J., Peterson K.L., McCulloch A.D., Yajima T., Knowlton K.U. Coxsackievirus and adenovirus receptor (CAR) mediates atrioventricular-node function and connexin 45 localization in the murine heart. J. Clin. Investig. 2008, 118(8):2758-2770.
15. Lim B.K., Yun S.H., Gil C.O., Ju E.S., Choi J.O., Kim D.K., Jeon E.S. Foreign gene transfer to cardiomyocyte using a replication-defective recombinant coxsackievirus B3 without cytotoxicity. Intervirology 2012, 55(3):201-209.
16. Pinkert S., Westermann D., Wang X., Klingel K., Dorner A., Savvatis K., Grossl T., Krohn S., Tschope C., Zeichhardt H., Kotsch K., Weitmann K., Hoffmann W., Schultheiss H.P., Spiller O.B., Poller W., Fechner H. Prevention of cardiac dysfunction in acute coxsackievirus B3 cardiomyopathy by inducible expression of a soluble coxsackievirus-adenovirus receptor. Circulation 2009, 120(23):2358-2366.
17. Sato S., Tsutsumi R., Burke A., Carlson G., Porro V., Seko Y., Okumura K., Kawana R., Virmani R. Persistence of replicating coxsackievirus B3 in the athymic murine heart is associated with development of myocarditic lesions. J. Gen. Virol. 1994, 75(Pt 11):2911-2924.
18. Wolfgram L.J., Beisel K.W., Rose N.R. Heart-specific autoantibodies following murine coxsackievirus B3 myocarditis. J. Exp. Med. 1985, 161(5):1112-1121.
19. Wolfgram L.J., Beisel K.W., Herskowitz A., Rose N.R. Variations in the susceptibility to Coxsackievirus B3-induced myocarditis among different strains of mice. J. Immunol. 1986, 136(5):1846-1852.
20. Xiong D., Yajima T., Lim B.K., Stenbit A., Dublin A., Dalton N.D., Summers-Torres D., Molkentin J.D., Duplain H., Wessely R., Chen J., Knowlton K.U. Inducible cardiac-restricted expression of enteroviral protease 2A is sufficient to induce dilated cardiomyopathy. Circulation 2007, 115(1):94-102.
21. Yun S.H., Lee W.G., Kim Y.C., Ju E.S., Lim B.K., Choi J.O., Kim D.K., Jeon E.S. Antiviral activity of coxsackievirus B3 3C protease inhibitor in experimental murine myocarditis. J. Infect. Dis. 2012, 205(3):491-497.